ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2020
Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Blood-based biomarkers for Alzheimer's disease in Down syndrome: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Blood biomarkers predict conversion from cognitively stable to mild cognitive impairment or Alzheimer's disease in Down syndrome at 16-month follow-up in ABC-DS.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The association between APOE 𝜀4 carrierships and the detection of amyloid positivity using an Alzheimer's disease proteomic blood test in asymptomatic Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS): A 10-year report.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Blood biomarkers in Down syndrome: Facilitating Alzheimer's disease detection and monitoring.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Microglia measured by TSPO PET are associated with Alzheimer's disease pathology and mediate key steps in a disease progression model.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Comorbidities Incorporated to Improve Prediction for Prevalent Mild Cognitive Impairment and Alzheimer's Disease in the HABS-HD Study.Journal of Alzheimer's disease : JAD · 2023Article
- Review
- Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Exploring the role of sex differences in Alzheimer's disease pathogenesis in Down syndrome.Frontiers in neuroscience · 2022Review
- Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study.Journal of Alzheimer's disease : JAD · 2022Article
- Role of tau deposition in early cognitive decline in Down syndrome.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- Alzheimer's disease associated with Down syndrome: a genetic form of dementia.The Lancet. Neurology · 2021Review
- Acute Regression in Down Syndrome.Brain sciences · 2021Article
- Blood Biomarkers for Alzheimer's Disease in Down Syndrome.Journal of clinical medicine · 2021Review
- Fatty Acid Binding Protein 3 (FABP3) and Apolipoprotein E4 (ApoE4) as Lipid Metabolism-Related Biomarkers of Alzheimer's Disease.Journal of clinical medicine · 2021Article
- Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome.Journal of Alzheimer's disease : JAD · 2021Article
- Alix: A Candidate Serum Biomarker of Alzheimer's Disease.Frontiers in aging neuroscience · 2021Article
- Postmortem NeocorticalFrontiers in aging neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
introductionPreviously generated serum and plasma proteomic profiles were examined among adults with Down syndrome (DS) to determine whether these profiles could discriminate those with mild cognitive impairment (MCI-DS) and Alzheimer's disease (DS-AD) from those cognitively stable (CS).
methodsData were analyzed on n = 305 (n = 225 CS; n = 44 MCI-DS; n = 36 DS-AD) enrolled in the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS).
resultsDistinguishing MCI-DS from CS, the serum profile produced an area under the curve (AUC) = 0.95 (sensitivity [SN] = 0.91; specificity [SP] = 0.99) and an AUC = 0.98 (SN = 0.96; SP = 0.97) for plasma when using an optimized cut-off score. Distinguishing DS-AD from CS, the serum profile produced an AUC = 0.93 (SN = 0.81; SP = 0.99) and an AUC = 0.95 (SN = 0.86; SP = 1.0) for plasma when using an optimized cut-off score. AUC remained unchanged to slightly improved when age and sex were included. Eotaxin3, interleukin (IL)-10, C-reactive protein, IL-18, serum amyloid A , and FABP3 correlated fractions at r DISCUSSION: Proteomic profiles showed excellent detection accuracy for MCI-DS and DS-AD.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.